• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    11/7/23 8:06:23 AM ET
    $AHI
    $AUGX
    $AURA
    $CHRS
    Package Goods/Cosmetics
    Consumer Discretionary
    Business Services
    Consumer Discretionary
    Get the next $AHI alert in real time by email

    Gainers

    • Senti Biosciences (NASDAQ:SNTI) stock increased by 139.8% to $0.7 during Tuesday's pre-market session. The market value of their outstanding shares is at $31.1 million.
    • Tharimmune (NASDAQ:THAR) stock increased by 78.18% to $0.28. The market value of their outstanding shares is at $4.9 million.
    • TransMedics Gr (NASDAQ:TMDX) shares moved upwards by 43.59% to $57.71. The company's market cap stands at $1.8 billion. As per the press release, Q3 earnings came out yesterday.
    • Synlogic (NASDAQ:SYBX) shares moved upwards by 19.15% to $2.55. The company's market cap stands at $21.6 million.
    • Advanced Health (NASDAQ:AHI) shares increased by 17.97% to $2.1. The market value of their outstanding shares is at $16.3 million.
    • Augmedix (NASDAQ:AUGX) stock moved upwards by 17.8% to $5.36. The market value of their outstanding shares is at $218.6 million. The company's, Q3 earnings came out yesterday.

    Losers

    • Ventyx Biosciences (NASDAQ:VTYX) shares fell 76.2% to $3.35 during Tuesday's pre-market session. The market value of their outstanding shares is at $197.2 million.
    • Aura Biosciences (NASDAQ:AURA) shares declined by 23.55% to $8.41. The company's market cap stands at $321.2 million.
    • Coherus BioSciences (NASDAQ:CHRS) stock decreased by 22.6% to $2.74. The market value of their outstanding shares is at $291.5 million. As per the news, the Q3 earnings report came out yesterday.
    • MSP Recovery (NASDAQ:LIFW) stock fell 11.82% to $8.51. The market value of their outstanding shares is at $114.0 million.
    • Clover Health Investments (NASDAQ:CLOV) shares declined by 11.51% to $1.0. The company's market cap stands at $484.8 million. The company's, Q3 earnings came out yesterday.
    • Trevena (NASDAQ:TRVN) shares decreased by 11.25% to $0.51. The market value of their outstanding shares is at $7.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AHI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHI
    $AUGX
    $AURA
    $CHRS

    CompanyDatePrice TargetRatingAnalyst
    Coherus Oncology Inc.
    $CHRS
    1/23/2026$10.00Outperform
    Oppenheimer
    Aura Biosciences Inc.
    $AURA
    11/26/2025$13.00Outperform
    Evercore ISI
    Ventyx Biosciences Inc.
    $VTYX
    11/5/2025$18.00Neutral → Buy
    H.C. Wainwright
    TransMedics Group Inc.
    $TMDX
    10/23/2025$148.00Hold → Buy
    Needham
    Senti Biosciences Inc.
    $SNTI
    10/14/2025$12.00Buy
    H.C. Wainwright
    TransMedics Group Inc.
    $TMDX
    10/13/2025$145.00Buy
    Jefferies
    TransMedics Group Inc.
    $TMDX
    9/16/2025$155.00Outperform
    Evercore ISI
    TransMedics Group Inc.
    $TMDX
    9/4/2025$115.00Hold
    Stifel
    More analyst ratings

    $AHI
    $AUGX
    $AURA
    $CHRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO of Home Care Priest Brady Patrick sold $379,750 worth of shares (175,000 units at $2.17), decreasing direct ownership by 8% to 1,998,584 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    3/5/26 4:16:16 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Chief Financial Officer Hernandez Gerardo sold $1,117,382 worth of shares (7,611 units at $146.81) and exercised 7,236 shares at a strike of $71.17, decreasing direct ownership by 2% to 14,689 units (SEC Form 4)

    4 - TransMedics Group, Inc. (0001756262) (Issuer)

    3/4/26 9:40:27 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Officer Ranganath Anil P. sold $120,200 worth of shares (864 units at $139.12), decreasing direct ownership by 6% to 13,091 units (SEC Form 4)

    4 - TransMedics Group, Inc. (0001756262) (Issuer)

    3/4/26 8:40:34 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AHI
    $AUGX
    $AURA
    $CHRS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for CIMERLI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug CIMERLI (SUPPL-5) with active ingredient RANIBIZUMAB-EQRN has changed to 'Approval' on 05/21/2024. Application Category: BLA, Application Number: 761165, Application Classification:

    5/22/24 9:41:01 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug LOQTORZI (SUPPL-1) with active ingredient TORIPALIMAB-TPZI has changed to 'Approval' on 04/22/2024. Application Category: BLA, Application Number: 761240, Application Classification:

    4/23/24 4:41:07 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for UDENYCA issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug UDENYCA (SUPPL-15) with active ingredient PEGFILGRASTIM-CBQV has changed to 'Approval' on 12/22/2023. Application Category: BLA, Application Number: 761039, Application Classification:

    12/27/23 4:38:39 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AHI
    $AUGX
    $AURA
    $CHRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Coherus BioSciences with a new price target

    Oppenheimer initiated coverage of Coherus BioSciences with a rating of Outperform and set a new price target of $10.00

    1/23/26 8:18:28 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evercore ISI resumed coverage on Aura Biosciences with a new price target

    Evercore ISI resumed coverage of Aura Biosciences with a rating of Outperform and set a new price target of $13.00

    11/26/25 8:36:10 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ventyx Biosciences upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Ventyx Biosciences from Neutral to Buy and set a new price target of $18.00

    11/5/25 7:25:28 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHI
    $AUGX
    $AURA
    $CHRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Hassanein Waleed H bought $1,000,350 worth of shares (8,775 units at $114.00) (SEC Form 4)

    4 - TransMedics Group, Inc. (0001756262) (Issuer)

    11/18/25 4:30:07 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Loengard Anna U bought $68,755 worth of shares (26,500 units at $2.59) (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/14/25 4:44:26 PM ET
    $CLOV
    Medical Specialities
    Health Care

    President & CEO Hassanein Waleed H bought $1,982,121 worth of shares (16,875 units at $117.46) (SEC Form 4)

    4 - TransMedics Group, Inc. (0001756262) (Issuer)

    8/8/25 4:30:13 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AHI
    $AUGX
    $AURA
    $CHRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $AHI
    $AUGX
    $AURA
    $CHRS
    SEC Filings

    View All

    Clover Health Moves from Pledge to Production, Becomes The First Payer Live on a CMS Aligned Network

    WILMINGTON, Del., March 04, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, and Kno2, healthcare's leading communication network, today announced a collaboration enabling Clover Health to be the first payer live on a CMS Aligned Network and TEFCA. Clover is demonstrating that nationwide, interoperable data exchange is not aspirational, it is achievable today. Through this collaboration, Clover Health now responds in real time to patient-directed requests for clinical and claims data using standardized FHIR (USCDI v3)

    3/4/26 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will present at the Leerink Partners 2026 Global Healthcare Conference in Miami, FL on Monday, March 9, 2026, at 2:20 PM ET. A webcast replay will be available on the Events page of the Investors section of the Company's website (sentibio.com). Interested parties may access the live video webcast here. About Senti Bio Senti Bio is a biotechnolog

    3/3/26 9:05:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

    REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4:30 p.m. Eastern Time on March 9, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, March 9, 2026, starting at 4:30 p.m. Eastern Standard Time To access the conference call, please pre-register

    3/2/26 9:30:00 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Ventyx Biosciences Inc.

    SCHEDULE 13D/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    3/5/26 9:00:30 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Ventyx Biosciences Inc.

    S-8 POS - Ventyx Biosciences, Inc. (0001851194) (Filer)

    3/4/26 12:06:38 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Ventyx Biosciences Inc.

    S-8 POS - Ventyx Biosciences, Inc. (0001851194) (Filer)

    3/4/26 12:05:06 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHI
    $AUGX
    $AURA
    $CHRS
    Financials

    Live finance-specific insights

    View All

    Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will present at the Leerink Partners 2026 Global Healthcare Conference in Miami, FL on Monday, March 9, 2026, at 2:20 PM ET. A webcast replay will be available on the Events page of the Investors section of the Company's website (sentibio.com). Interested parties may access the live video webcast here. About Senti Bio Senti Bio is a biotechnolog

    3/3/26 9:05:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

    REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4:30 p.m. Eastern Time on March 9, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, March 9, 2026, starting at 4:30 p.m. Eastern Standard Time To access the conference call, please pre-register

    3/2/26 9:30:00 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Clover Health Reports Fourth Quarter & Full Year 2025 Results; Provides Full Year 2026 Guidance

    Business Highlights: Generated full year 2025 Adjusted EBITDA profitability while growing membership by 38% and Insurance revenue by 41% year-over-yearAchieved industry-leading 2026 AEP growth of 53% year-over-year with strong returning member retentionExpect improving cohort economics powered by Clover Assistant to drive our first-ever full year of GAAP Net Income profitability in 2026 Financial Results: Full year 2025 Medicare Advantage membership of 113,803, up 38% year-over-yearFull year 2025 Total revenues of $1.9 billion, up 40% year-over-yearFull year 2025 GAAP Net loss of $86 million, Adjusted EBITDA of $22 million, and Adjusted Net Income of $20 million Full Year 2026 Gu

    2/26/26 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $AHI
    $AUGX
    $AURA
    $CHRS
    Leadership Updates

    Live Leadership Updates

    View All

    Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

    Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

    2/6/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Elects Jill Sommers and William Wiley to Board of Directors

    New Directors Strengthen Governance as Company Advances Canton Network Infrastructure Former CFTC Commissioner Jill Sommers Brings Decades of Regulatory and Public Policy Experience DRW Chief of Staff William Wiley, CFA, Adds Extensive Leadership Experience Across Capital Markets and Global Operations NEW YORK, Feb. 2, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Jill Sommers and William Wiley, CFA, to the Board, effective February 1, 20

    2/2/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer

    ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a late-stage biopharmaceutical company, today announced the appointment of Jean-Frédéric Viret, Ph.D., as the company's Chief Financial Officer (CFO). Dr. Viret brings over two decades of corporate finance experience in the life sciences industry, leading companies from early-stage clinical development through post-commercialization. At SpyGlass, he will lead the finance and accounting functions as the company advances the Bimatoprost Drug Pad-IOL System (BIM-IOL System) toward late-stage development and potential commercialization. "We are excited to welcome Jean to SpyGlass Pharma as we continue to advance our clin

    1/6/26 8:00:00 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AHI
    $AUGX
    $AURA
    $CHRS
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

    The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

    6/20/24 6:36:05 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $AHI
    $AUGX
    $AURA
    $CHRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13D/A filed by Senti Biosciences Inc.

    SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)

    12/4/24 7:08:03 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

    SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/24 7:54:08 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care